Holen Sie sich die Stockscreener-App
28.33
0.75%
0.21
Handel nachbörslich:
28.52
0.19
+0.67%
Schlusskurs vom Vortag:
$28.12
Offen:
$28.25
24-Stunden-Volumen:
128.96K
Relative Volume:
0.53
Marktkapitalisierung:
$812.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-56.91M
KGV:
-11.52
EPS:
-2.46
Netto-Cashflow:
-
1W Leistung:
+3.89%
1M Leistung:
-7.81%
6M Leistung:
+71.39%
1J Leistung:
+0.00%
1-Tages-Spanne:
$28.08
$29.15
1-Wochen-Bereich:
$27.19
$29.71
52-Wochen-Spanne:
$13.36
$33.47
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Firmenname
Lb Pharmaceuticals Inc
Sektor
Branche
Telefon
917-450-6581
Adresse
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
28.33 | 806.39M | 0 | -56.91M | 0 | -2.46 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-09 | Eingeleitet | Roth Capital | Buy |
| 2025-10-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-06 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-06 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
Clear Street initiates LB Pharmaceuticals stock with buy rating - Investing.com
Clear Street initiates LB Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential - TipRanks
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy - Yahoo Finance
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target - Investing.com
LB Pharmaceuticals Inc (LBRX) Holds Steady Near Resistance as Market Watches for BreakoutCovered Call Trade - Newser
LB Pharmaceuticals Inc (LBRX) Breaks Higher as Volume Picks Up; Key Resistance AheadRetail Trader Picks - Newser
Why Is LB Pharmaceuticals Inc Common Stock (LBRX) Stock Down Today? - Meyka
LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans - Sahm
Number of shareholders of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
TCG Crossover entities report 1.84M shares in LB Pharmaceuticals (LBRX) - Stock Titan
Commodore Capital (LBRX) files Schedule 13G/A reporting 1.97M shares - Stock Titan
Caligan Partners discloses 1.44M shares in LB Pharmaceuticals (LBRX) - Stock Titan
Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX) - The Globe and Mail
LB Pharmaceuticals (LBRX) Declines -1.02% Amid Market Weakness 2026-05-14Inverse ETF Flow - Newser
JPMorgan (NYSE: JPM) files amendment showing 1.43M LBRX shares (4.9%) - Stock Titan
This LB Pharmaceuticals analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
LBRX: LB-102 demonstrates rapid efficacy and strong safety in late-stage trials for major neuropsychiatric disorders - TradingView
LB Pharmaceuticals (LBRX) reports $365.6M cash, Q1 net loss $19.1M - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) boosts cash for late-stage LB-102 trials - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) ramps LB-102 trials with $365.6M cash runway to 2029 - Stock Titan
New schizophrenia and bipolar trials backed by $365.6M at LB Pharmaceuticals - Stock Titan
LB Pharmaceuticals Q1 net loss widens on higher R&D costs - TradingView
LB Pharmaceuticals Inc.: Q1 Earnings Snapshot - Barchart.com
TradingKey - TradingKey
Why LB Pharmaceuticals (LBRX) is still under the radar (+3.85%) 2026-05-11Popular Trader Picks - Newser
How will LB Pharmaceuticals (LBRX) earnings compare to expectations | Q4 2025: Profit Exceeds ViewsTrading Community - Newser
Is LB Pharmaceuticals (LBRX) the most overlooked stock right now? (Modest Decline) 2026-05-06Reward Analysis - newser.com
Jennison Associates LLC Acquires 82,812 Shares of LB Pharmaceuticals Inc $LBRX - MarketBeat
LBRX LB Pharmaceuticals posts slightly smaller Q4 2025 loss than analyst estimates, shares rise 3.66 percent.High Attention Stocks - newser.com
LBRX Forecast — Price Target — Prediction for 2027 - TradingView
LBRX News Today | Why did LB Pharmaceuticals stock go down today? - MarketBeat
Equities Analysts Offer Predictions for LBRX Q1 Earnings - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighWhat's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading 5.6% HigherTime to Buy? - MarketBeat
This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biopharma breaks its lengthy IPO drought - MSN
Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (LBRX) and West Pharmaceutical Services (WST) - The Globe and Mail
Finanzdaten der Lb Pharmaceuticals Inc-Aktie (LBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lb Pharmaceuticals Inc-Aktie (LBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):